Matches in Wikidata for { <http://www.wikidata.org/entity/Q87163239> ?p ?o ?g. }
- Q87163239 description "article scientifique publié en 2014" @default.
- Q87163239 description "artículu científicu espublizáu en xineru de 2014" @default.
- Q87163239 description "im Januar 2014 veröffentlichter wissenschaftlicher Artikel" @default.
- Q87163239 description "scientific article published on 04 January 2014" @default.
- Q87163239 description "wetenschappelijk artikel" @default.
- Q87163239 description "наукова стаття, опублікована в січні 2014" @default.
- Q87163239 description "գիտական հոդված հրատարակված 2014 թվականի հունվարի 4-ին" @default.
- Q87163239 name "Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i" @default.
- Q87163239 name "Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i" @default.
- Q87163239 type Item @default.
- Q87163239 label "Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i" @default.
- Q87163239 label "Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i" @default.
- Q87163239 prefLabel "Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i" @default.
- Q87163239 prefLabel "Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with i" @default.
- Q87163239 P1433 Q87163239-2072B511-019A-4A65-BA73-D3ACA5F9C5FF @default.
- Q87163239 P1476 Q87163239-91FE0F07-A484-4EAD-ABC4-3D055E1094FA @default.
- Q87163239 P2093 Q87163239-0376E8A1-8A18-481E-869C-EE1D1B221974 @default.
- Q87163239 P2093 Q87163239-233649D4-30BA-4F64-B3A4-06F7319ACEB4 @default.
- Q87163239 P2093 Q87163239-3385AC14-1221-4241-A54E-D2AA0C84EFF1 @default.
- Q87163239 P2093 Q87163239-5DAED855-758B-41DA-8ABE-FE22FF4E9DAA @default.
- Q87163239 P2093 Q87163239-791C6DE0-E33D-483C-B552-E247134F5904 @default.
- Q87163239 P2093 Q87163239-8D213435-BAA0-4BC0-A6BE-0DC03DDD787A @default.
- Q87163239 P2093 Q87163239-8EAE690B-F8D4-42BA-8C66-DF0165B5DF37 @default.
- Q87163239 P2093 Q87163239-C814B68F-7183-49DC-A928-5869E7F30A98 @default.
- Q87163239 P2093 Q87163239-CAB68763-EC6D-48E8-96CF-2CE2D69EEB93 @default.
- Q87163239 P2093 Q87163239-D959CC6A-11FC-4934-8FCF-1D0133C632C2 @default.
- Q87163239 P2860 Q87163239-12DEAC0D-B495-454B-AF5D-285F4C0A7025 @default.
- Q87163239 P2860 Q87163239-18DE769F-37B8-408F-8073-CCDB3DECE1AD @default.
- Q87163239 P2860 Q87163239-2A7297DB-D31A-4010-B96D-F719AABDF23D @default.
- Q87163239 P2860 Q87163239-3494B8B4-6D15-418B-BDAF-13FFF57B4821 @default.
- Q87163239 P2860 Q87163239-36C66146-A7C4-441C-91B3-D9AEF9358A8A @default.
- Q87163239 P2860 Q87163239-4CDEF7B7-4A4C-4EC3-90EC-9DE8E8FAFA50 @default.
- Q87163239 P2860 Q87163239-5022AC83-CF30-4E85-AFBD-82E4D87A043F @default.
- Q87163239 P2860 Q87163239-5152F680-C653-49BB-9522-EF55956B3E9C @default.
- Q87163239 P2860 Q87163239-56021ED7-AF54-4F2E-A0BB-B555DCBB3A16 @default.
- Q87163239 P2860 Q87163239-60E69AEE-71EE-408A-9787-364221168A2C @default.
- Q87163239 P2860 Q87163239-616BF253-0B01-4658-8EDA-D0DA6B5234B6 @default.
- Q87163239 P2860 Q87163239-71BF1D13-FC96-4BEE-B91F-CF80BC43C948 @default.
- Q87163239 P2860 Q87163239-7BACFA22-35AF-461F-87E9-922E126FF24B @default.
- Q87163239 P2860 Q87163239-7EAB8593-4CB8-4334-B72E-16747D20C908 @default.
- Q87163239 P2860 Q87163239-7F8ACD7D-1F1E-4E56-A286-ABF509662BA5 @default.
- Q87163239 P2860 Q87163239-86ED4EFF-1030-4305-9642-4D0A92503091 @default.
- Q87163239 P2860 Q87163239-880C1CAF-A784-4CE9-9204-428D93A554D0 @default.
- Q87163239 P2860 Q87163239-8E838929-DA4A-4210-829E-08C6022EF52E @default.
- Q87163239 P2860 Q87163239-9301DDBC-B963-4676-BDB5-EAC69D508419 @default.
- Q87163239 P2860 Q87163239-94DABB4C-263A-49C0-95A3-26511B5281DC @default.
- Q87163239 P2860 Q87163239-981D3ED0-8677-4441-B586-A2D7A42163FA @default.
- Q87163239 P2860 Q87163239-AAEE8C6D-0917-487C-81C3-F957289FD98C @default.
- Q87163239 P2860 Q87163239-AD60F06A-6044-4B7C-A72A-2B55922B83E7 @default.
- Q87163239 P2860 Q87163239-B27DCD98-57DA-455F-9138-910B8F127242 @default.
- Q87163239 P2860 Q87163239-C2E26F64-4DD9-4148-BA36-C5FB34591797 @default.
- Q87163239 P2860 Q87163239-C3FDEB9D-8A17-4B62-A014-38FDE6162914 @default.
- Q87163239 P2860 Q87163239-DEAE5D2B-2555-4BDB-BAA5-6C70547E4C5B @default.
- Q87163239 P2860 Q87163239-E4E7A383-4D5E-4224-A24C-98F05162B67B @default.
- Q87163239 P2860 Q87163239-E76CD923-D1A0-4FE6-9225-C59415019D10 @default.
- Q87163239 P2860 Q87163239-F88120F2-A971-48F3-8597-CEC86854670F @default.
- Q87163239 P304 Q87163239-9065BAA4-C238-47F0-86F3-0B38EC91332F @default.
- Q87163239 P31 Q87163239-9679CC86-AD2E-4084-8390-7788D90644DE @default.
- Q87163239 P356 Q87163239-2F07A425-30CD-408B-8C71-048CC060B4AC @default.
- Q87163239 P433 Q87163239-102952DF-0030-44B0-8C0C-1E5AD5A83729 @default.
- Q87163239 P478 Q87163239-AFF5F37E-D5F3-490D-A76E-23A65547316F @default.
- Q87163239 P577 Q87163239-E764437D-7C39-4746-9928-1D1619E7FBCE @default.
- Q87163239 P698 Q87163239-98D0FEC4-2882-4828-9893-5BD9679D2CCB @default.
- Q87163239 P921 Q87163239-06872852-CB24-4771-8396-9B5D4D814D81 @default.
- Q87163239 P921 Q87163239-4F6210FC-0DCF-475F-A03D-CE719DACE77D @default.
- Q87163239 P921 Q87163239-63825BDE-8C9B-4348-BBD8-C6C024E0E836 @default.
- Q87163239 P921 Q87163239-CC8AD91A-0E81-4852-94AA-33A1A5C64A91 @default.
- Q87163239 P921 Q87163239-FCBE6DF9-249F-47DA-9755-CDF108639942 @default.
- Q87163239 P356 J.TRSL.2013.12.009 @default.
- Q87163239 P698 24462762 @default.
- Q87163239 P1433 Q15761127 @default.
- Q87163239 P1476 "Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting" @default.
- Q87163239 P2093 "Chien-Yu Lu" @default.
- Q87163239 P2093 "Ching-Wen Huang" @default.
- Q87163239 P2093 "Chun-Ming Huang" @default.
- Q87163239 P2093 "Fang-Jung Yu" @default.
- Q87163239 P2093 "Hsiang-Lin Tsai" @default.
- Q87163239 P2093 "Huang-Ming Hu" @default.
- Q87163239 P2093 "Jaw-Yuan Wang" @default.
- Q87163239 P2093 "Meng-Lin Huang" @default.
- Q87163239 P2093 "Ming-Yii Huang" @default.
- Q87163239 P2093 "Se-Fen Chang" @default.
- Q87163239 P2860 Q22241238 @default.
- Q87163239 P2860 Q26822395 @default.
- Q87163239 P2860 Q27860681 @default.
- Q87163239 P2860 Q27860904 @default.
- Q87163239 P2860 Q28036747 @default.
- Q87163239 P2860 Q28240089 @default.
- Q87163239 P2860 Q28265991 @default.
- Q87163239 P2860 Q33990876 @default.
- Q87163239 P2860 Q34374626 @default.
- Q87163239 P2860 Q34511070 @default.
- Q87163239 P2860 Q35035611 @default.
- Q87163239 P2860 Q35050772 @default.
- Q87163239 P2860 Q35108413 @default.
- Q87163239 P2860 Q36533867 @default.
- Q87163239 P2860 Q36915163 @default.
- Q87163239 P2860 Q37298982 @default.
- Q87163239 P2860 Q37345971 @default.
- Q87163239 P2860 Q37345974 @default.